exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089267 RNA Name: hsa-miR-641 RNA Type: miRNA Chromosome: chr19 Starnd: - Coordinate: Start Site(bp): 40282603 End Site(bp): 40282626 External Links: hsa-miR-641

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AIF1L chr9 131096476 131123152 + AKT2 chr19 40230317 40285536 - C19orf47 chr19 40319536 40348527 - CDKN1A chr6 36676460 36687339 + F11R chr1 160995211 161021343 - FOXN3 chr14 89124871 89619149 - GATAD2B chr1 153789030 153923360 - GCNT2 chr6 10492223 10629368 + GNPTAB chr12 101745499 101830959 - HMGA2 chr12 65824131 65966295 + ICE1 chr5 5420664 5490220 + JPT1 chr17 75135248 75168281 - LSM14A chr19 34172504 34229515 + MED13L chr12 115953872 116277719 - PRSS16 chr6 27247701 27256624 + SETD7 chr4 139495941 139606699 - SOCS3 chr17 78356778 78360077 - SYNJ2BP chr14 70366499 70417090 - SYNJ2BP-COX16 chr14 70326064 70417074 - ZDHHC6 chr10 112424428 112446917 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001085 chr2 191765289 191789319 + hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC125257.1 chr17 41848518 41851447 - AC239868.1 chr1 149861271 149862504 + AL034397.3 chrX 66015461 66020422 + AL049795.2 chr1 32170733 32176568 + AL355075.4 chr14 20343048 20343685 - DLEU2 chr13 49956670 50125720 - LINC00641 chr14 21200079 21206900 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + SNHG1 chr11 62851984 62855953 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.